Company: ANTX
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001193125-25-277673
Chunk: 0

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 0
---
AN2 THERAPEUTICS, INC.

CONDENSED BALANCE SHEETS

(in thousands, except share and per share amounts)

(unaudited)

     September 30,

     December 31,

     2025

     2024

     Assets

     Current assets:

     Cash and cash equivalents
      
     $
     18,003

     $
     21,351

     Short-term investments

     43,918

     62,267

     Prepaid expenses and other current assets

     2,095

     2,644

     Total current assets

     64,016

     86,262

     Long-term investments

     3,219

     5,021

     Other assets, long-term

     —

     804

     Total assets
      
     $
     67,235

     $
     92,087

     Liabilities and stockholders’ equity

     Current liabilities:

     Accounts payable
      
     $
     2,226

     $
     3,317

     Accrued compensation

     1,744

     1,676

     Accrued liabilities

     2,705

     4,454

     Other current liabilities

     183

     791

     Total liabilities

     6,858

     10,238

     Commitments and contingencies (Note 7)

     Stockholders’ equity:

     Preferred stock, $0.00001 par value; 10,000,000 shares authorized at September 30, 2025 and December 31, 2024; no shares issued and outstanding at September 30, 2025 and December 31, 2024

     —

     —

     Common stock, $0.00001 par value; 500,000,000 shares authorized at September 30, 2025 and December 31, 2024; 27,371,154 and 29,919,634 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively

     —

     —

     Additional paid-in capital

     292,553

     287,594

     Accumulated other comprehensive gain

     64

     31

     Accumulated deficit

     (232,240
     )

     (205,776
     )

     Total stockholders